At week 24 , reductions in HbA1c ( mean baseline 7.90-8 .02 % [ 62.8-64 .1 mmol/mol ] ) with empagliflozin/linagliptin were superior to those with empagliflozin or linagliptin alone as add-on to metformin ; adjusted mean ( SE ) changes from baseline were -1.19 % ( 0.06 ) ( -13.1 mmol/mol [ 0.7 ] ) with empagliflozin 25 mg/linagliptin 5 mg , -1.08 % ( 0.06 ) ( -11.8 mmol/mol [ 0.7 ] ) with empagliflozin 10 mg/linagliptin 5 mg , -0.62 % ( 0.06 ) ( -6.8 mmol/mol [ 0.7 ] ) with empagliflozin 25 mg , -0.66 % ( 0.06 ) ( -7.2 mmol/mol [ 0.7 ] ) with empagliflozin 10 mg , and -0.70 % ( 0.06 ) ( -7.6 mmol/mol [ 0.7 ] ) with linagliptin 5 mg ( P < 0.001 for all comparisons ) .